Abstract: The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Abstract: Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
Abstract: Extended-release, injectable microsphere formulations comprising ketamine are provided. Methods for making and using the microsphere formulations are also provided.
Abstract: Methods and compositions for treating a myelofibrosis with an agent that depletes, or inhibits proliferation of, Sox10+ glial cells in a subject and/or ErbB3+ glial cells in a subject.
Type:
Application
Filed:
April 8, 2024
Publication date:
October 17, 2024
Inventors:
Lei Ding, Shawn M. Sarkaria, Junsong Zhou
Abstract: The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.
Type:
Application
Filed:
May 23, 2024
Publication date:
October 17, 2024
Applicant:
De Motu Cordis Pty Ltd
Inventors:
John Fraser, Sean Dalziel, Teresa Iley, Jonathan Brazier, Patrick Joseph Lynch, John Fredatovich, Benjamin Barnaby Trout
Abstract: Provided herein are compositions and methods of providing an effective amount of an N-acetylcysteine amide (NACA) or diNACA sufficient to increase the concentration of NACA or diNACA in the affected tissue to biochemically reduce oxidative stress-related damage to tissue; utilizing NACA or diNACA that comprises at least one of impurities B1 or B2, which are indicative of NACA or diNACA manufactured by a process comprising: contacting cystine with methanol and a chlorinating reagent to form an organic solution containing cystine dimethylester dihydrochloride and optionally isolating and drying the cystine dimethylester dihydrochloride; combining the dried or undried cystine dimethylester dihydrochloride with triethylamine, acetic anhydride, and acetonitrile to form di-N-acetylcystine dimethylester; mixing the di-N-acetylcystine dimethylester with ammonium hydroxide to form di-N-acetylcystine amide (diNACA or NPI-002); and reducing the di-N-acetylcystine amide to N-acetylcysteine, NACA or NPI-001 with a reducin
Type:
Application
Filed:
May 30, 2024
Publication date:
October 17, 2024
Inventors:
G. Michael Wall, Doug G. Johnson, Anja Rubenstein, Rodney Tucker, Josh Bolger, Marcin Jakub Kowalczyk, Craig Sheehan, Gerald D. Cagle
Abstract: The present invention relates to a composition for treating hypertrophic scars and keloids, comprising a benzhydryl thioacetamide compound as an active ingredient. The benzhydryl thioacetamide compound inhibits cell proliferation and an increase in intracellular Ca2+ concentration, in fibroblasts, keratinocytes and vascular endothelial cells that are involved in skin fibrosis, and inhibits the synthesis of collagen, which is the extracellular matrix, and thus has the effect of effectively treating intractable hypertrophic scars and keloids.
Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Application
Filed:
June 25, 2024
Publication date:
October 17, 2024
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: Described herein are methods for treating a subject with an aneurysm or a dissection in a blood vessel comprising administering to the subject an effective amount of a ?-hydroxybutyrate. The methods described herein are useful in repairing damage to arteries caused by an aneurysm. Additionally, described herein are methods for reducing or preventing the risk of the formation of aneurysm or dissection in a blood vessel comprising administering to the subject an effective amount of a ?-hydroxy butyrate.
Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.
Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.
Type:
Application
Filed:
April 15, 2024
Publication date:
October 17, 2024
Inventors:
Liat Adar, Nelson Felix Lopes, Laurence Salin, Tamar Yardeni, Nissim Sasson, Sheila Oren, Hikari Yarita, Mikio Himizu, Natalia Vostokova
Abstract: A method for inhibiting the generation of diclofenac indolinones in an adhesive patch is provided. This adhesive patch comprises a support body layer and an adhesive layer that is layered on the support body layer. The aforementioned method includes a step for mixing a diclofenac free acid and an adhesive base to acquire an adhesive composition, and a step for shaping the adhesive composition to obtain an adhesive patch. The content of the diclofenac free acid is 0.5-8 mass % on the basis of the total mass of the adhesive layer.
Abstract: The present application relates to combination compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof. The present application also relates to intranasal pharmaceutical compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof. For example, the one or more hallucinogens is 5-methoxy-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof and the one or more fatty acids is linoleic acid.
Type:
Application
Filed:
May 26, 2022
Publication date:
October 17, 2024
Applicant:
Mindset Pharma Inc.
Inventors:
Abdelmalik Slassi, Joseph Araujo, Guy Andrew Higgins, Joseph Gabriele
Abstract: Disclosed are methods of treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old. Also disclosed are compositions comprising bis-choline tetrathiomolybdate for use in the treatment of a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old. Also disclosed are uses of a composition comprising bis-choline tetrathiomolybdate for the manufacture of a medicament for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old.
Abstract: The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.
Type:
Application
Filed:
June 24, 2024
Publication date:
October 17, 2024
Inventors:
Shiladitya SENGUPTA, Aniruddha SENGUPTA, Sanghamitra MYLAVARAPU, Monideepa ROY
Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
Type:
Application
Filed:
June 24, 2024
Publication date:
October 17, 2024
Inventors:
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Abstract: Stable liquid formulations dominant in cannabidiol (CBD) can be manufactured by a sequential process of purification to create a formulation that does not crystallize under a variety of storage and use conditions, and without the use of potentially harmful additives. For example, the formulation may be used in vaporization devices (i.e., electronic cigarettes) that typically require formulations to remain in a non-crystalline, non-solid, or non-partially solid state. The liquid formulations dominant in CBD may further contain other phytocannabinoids, including, but not limited to, tetrahydrocannabinol (THC), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV) in higher concentrations than unrefined and refined cannabis extracts obtained via existing methods.
Abstract: The present disclosure provides a multivitamin specifically formulated for patients undergoing CFTR modulator therapy. The multivitamin includes, in various embodiments, pro-vitamin A, vitamin E, a solubilizer, a bile fluid secretion stimulator, vitamin C and a probiotic formulation.
Abstract: Certain embodiments of the present disclosure provide storage-stable, aqueous pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of that is from 2% w/v to 7.5% w/v topiramate, from 45% w/v to 75% w/v PEG 400, from 6% w/v to 12% w/v water, balance glycerol. In some embodiments, such formulations further comprise a sweetener (e.g., sucralose) and/or a flavorant (e.g., berry flavor).
Type:
Application
Filed:
April 11, 2023
Publication date:
October 17, 2024
Applicant:
TaP Pharmaceuticals, AG
Inventors:
Nilesh PARIKH, William HITE, Kartik SHAH
Abstract: The invention relates to methods and compositions for treating lichen sclerosus and/or psoriasis by administering to a patient in need thereof a topical pharmaceutical formulation comprising simvastatin 1.07-5.0% w/w/in a non-aqueous, low pH, biphasic liposomal-PEG carrier.
Abstract: The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune-mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).
Abstract: Disclosed is the use of a nitrate and vitamin C microcapsule in the preparation of a drug for treating sicca syndrome. The microcapsule comprises a wall material and a core material encapsulated in the wall material, wherein the core material comprises vitamin C and nitrate, and a molar ratio of nitrate ions to vitamin C is 1:1 to 5:1.
Type:
Application
Filed:
March 25, 2022
Publication date:
October 17, 2024
Applicants:
CAPITAL MEDICAL UNIVERSITY, BEIJING STOMATOLOGICAL HOSPITAL, CAPITAL MEDICAL UNIVERSITY
Inventors:
Songling WANG, Yuji WANG, Lizheng QIN, Liang HU, Lei HU, Guoqing LI
Abstract: Provided herein is a method of treating a disease associated with activation of mast cells in a patient. The method comprises administering to the patient an amount of a GluR6 glutamate receptor agonist effective to reduce responsiveness of a mast cell in the patient. Pharmaceutical compositions comprising a GluR6 glutamate receptor agonist also are provided.
Abstract: An embodiment includes a composition for reversing an alpha-2 adrenoceptor agonist in a subject comprising an alpha-2 antagonist and a histidine in a pharmaceutically acceptable formulation. The embodiment includes where the composition comprises a pi-pi interaction between the alpha-2 antagonist and the histidine. The embodiment also includes where the alpha-2 antagonist comprises from about 80 mg/mL to 97.6 mg/mL.
Abstract: Provided are methods for treating cancers responsive to the modulation of microtubule assembly and P-gp-mediated resistant cancers using 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
April 15, 2024
Publication date:
October 17, 2024
Inventors:
Vivek K. VISHNUDAS, Maria-Dorothea Nastke, Stephane Gesta
Abstract: The present disclosure is concerned with substituted thiochromenothiazole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of neurodegenerative disorders associated with dysregulation of MSUT2 signaling such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), motor neuron disease, ataxia, progressive supranuclear palsy (PSP), multiple system atrophy, corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Pick's disease (PiD), dementia, Huntington's disease (HD), primary age-related tauopathy (PART), and aging-related tau astrogliopathy (ARTAG). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Abstract: Disclosed herein are liquid compositions and methods for treating hair loss by topical administration of the liquid compositions to a subject in need thereof.
Abstract: The present invention provides a method for treating or preventing a renal injury-related disease such as diabetic nephropathy comprising administering to a mammal a therapeutically effective amount of 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid or a pharmaceutically acceptable salt thereof, and a novel pharmaceutical use of the aforementioned compound such as a pharmaceutical composition for treating or preventing a renal injury-related disease and the like comprising the aforementioned compound or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
November 7, 2023
Publication date:
October 17, 2024
Inventors:
Kenji Fukui, Yuichi Shinozaki, Koji Inagaki
Abstract: The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
Abstract: The disclosure provides a use of an alkaloid compound Hip in treatment and/or prevention of cardiac trauma. Upon studying activity of the alkaloid compound Hip, it is verified that the alkaloid compound Hip provided in the disclosure can inhibit apoptosis induced by cardiomyocyte toxicity, through down-regulating expression levels of p-JNK and/or Cleaved-Caspase-3 to inhibit anthracycline DOX-induced cardiomyocyte apoptosis, thereby alleviating cardiomyocyte toxicity to achieve treatment and/or prevention of cardiomyocyte toxicity. Thus, the alkaloid compound Hip can be used to manufacture a medicine for treatment and/or prevention of myocardial injury-related diseases.
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
June 21, 2024
Publication date:
October 17, 2024
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof. comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
June 21, 2024
Publication date:
October 17, 2024
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The disclosure relates to chemotherapy treatments and in particular, formulations for antiemetic therapy. Parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid is provided. Also provided is a process of preparing such formulations.
Type:
Application
Filed:
June 25, 2024
Publication date:
October 17, 2024
Applicant:
LEIUTIS PHARMACEUTICALS LLP
Inventors:
Chandrashekhar KOCHERLAKOTA, Nagaraju BANDA
Abstract: The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.
Abstract: Provided herein, in part, are methods of treating facioscapulohumeral muscular dystrophy in a patient in need thereof, comprising administering losmapimod to the patient.
Type:
Application
Filed:
July 27, 2022
Publication date:
October 17, 2024
Inventors:
Michelle Mellion, John Jiang, Anthony Accorsi, Alejandro Rojas
Abstract: A pharmacologic treatment of refractive disorders, specifically myopia or hyperopia, by targeting the PPAR signaling pathway using a PPAR? agonist without any binding to PPAR?. It is demonstrated that the PPAR? agonist modulates ocular growth through therapeutic intervention at the protein level of the PPAR signaling pathway. The effectiveness of the PPAR? agonist in regulating the PPAR signaling pathway and its associated proteins, as evidenced by experiments using a lens-induced myopia (LIM) animal model. More particularly, it is also demonstrated that the pharmacological reduction of myopic eye growth in terms of biometrics with dosage effect through the administration of the PPAR? agonist.
Abstract: The present invention relates to Raloxifene or a pharmaceutically acceptable salt thereof for use in the treatment of an infection caused by one or more variants of SARS-CoV-2 in a subject.
Type:
Application
Filed:
August 3, 2022
Publication date:
October 17, 2024
Inventors:
Andrea Rosario BECCARI, Daniela IACONIS, Carmine TALARICO, Candida MANELFI, Laura SCORZOLINI, Licia BORDI, Giulia MATUSALI, Emanuele NICASTRI
Abstract: The compounds of the current disclosure include propynyl substituted indoles, where one or more hydrido radicals is substituted with a deuterium atom, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.
Abstract: Embodiments of the invention relate generally to the treatment of schizophrenia or bipolar I disorder and, more particularly, the administration of iloperidone, including titrated administration of iloperidone, a pharmaceutically-acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically-acceptable salt of a metabolite of iloperidone in such treatment. A first aspect of the invention provides a method of treating a patient suffering from bipolar I disorder, the method comprising: administering to the patient an effective amount of iloperidone, a pharmaceutically-acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically-acceptable salt of a metabolite of iloperidone, wherein the effective amount is an amount effective to improve at least one symptom of mania in the patient.
Abstract: Embodiments of the invention related generally to the treatment or prevention of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, more particularly, to the use of (S)-crizotinib or a pharmaceutically-acceptable salt thereof in such treatment or prevention. In one embodiment, the invention provides a method of treating a patient diagnosed with SARS-CoV-2, the method comprising: administering to the patient a dose of (S)-crizotinib or a pharmaceutically-acceptable salt thereof.
Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
Type:
Application
Filed:
June 26, 2024
Publication date:
October 17, 2024
Applicant:
Vyluma Inc.
Inventors:
Navneet Puri, Prem Sagar Akasapu, Irfan Ali Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
Abstract: Pharmaceutical compositions and formulations containing hydroxychloroquine having improved safety and tolerability are disclosed herein. In addition, methods of treating disease conditions, including autoimmune diseases, retinopathy and endometriosis. with such compositions and formulations are disclosed.
Type:
Application
Filed:
July 21, 2022
Publication date:
October 17, 2024
Inventors:
Beat WEIDMAN, Dan H. KIM, Mark CONNELL, John CARTER
Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Type:
Application
Filed:
January 17, 2024
Publication date:
October 17, 2024
Applicant:
Xenon Pharmaceuticals Inc.
Inventors:
James Philip Johnson, JR., Gregory N. Beatch
Abstract: This disclosure relates to activators of Bak, pharmaceutical compositions, and uses in treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a Bak activator as disclosed herein to a human subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a Bak activator which is 1-((2-((2-methoxyacridin-9-yl)amino)ethyl)amino)propan-2-ol (BKA-073), derivative, ester, or salt thereof and a pharmaceutically acceptable excipient.
Abstract: This disclosure provides methods of treating and/or preventing type 1 diabetes (T1D) and/or a syndrome including type 1 diabetes and autoimmune thyroiditis in a subject. The methods include administering a therapeutically effective amount of cepharanthine or a pharmaceutically acceptable salt, solvate or derivative thereof to the subject, wherein the subject has a human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype.
Abstract: Provided herein are methods for the add-on treatment of schizophrenia using a vesicular monoamine transporter isoform 2 (VMAT2) inhibitor. In certain embodiments, the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt thereof.
Abstract: Provided is a method of treating dyskinesia due to cerebral palsy in a patient in need thereof, comprising: administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to the patient in need thereof.
Abstract: The disclosed invention relates to compositions and methods of administration to a subject, with bisbenzylisoquinolines such as 6,6?,7,12-tetramethoxy-2,2?-dimethyl-berbaman (tetrandrine, TET and ES-3000), and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents which modulate ?-catenin and/or CaMKII? levels to either improve therapeutic outcome by enhancing expression of targets and/or decrease side effects of therapeutic regimens involving immunotherapies, such as checkpoint inhibitors and Chimeric antigen receptor T-cells (CAR-T).
Type:
Application
Filed:
March 14, 2024
Publication date:
October 17, 2024
Inventors:
Saira S. Bates, Dennis Brown, Shawnya Michaels
Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Type:
Application
Filed:
March 22, 2024
Publication date:
October 17, 2024
Applicant:
Ipsen Biopharm Ltd.
Inventors:
Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim